The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.00:55: The challenges of liver disease04:44: How Lexogen supports NGS drug discovery07:29: Major transcriptomics developments10:05: Designing high quality AI data15:47: How the Ochre-Lexogen partnership began17:17: Why a specialist partner is essential for scale18:21: Lexogen delivers on the massive sequencing project21:50: Why high quality data is crucial27:02: Lexogen's role in AI discovery34:51: Future plans and directionsThis episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Deep phenotyping brings accuracy to precision medicineSpatial Transcriptomics: A window into diseaseSpatial Transcriptomics Landscape Shifts With Two Major Acquisitions